A Phase 2 interventional study of LDX-01 plus TAU and Placebo plus TAU in Methamphetamine Abuse, Methamphetamine-dependence and Addiction, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 1 site in Canada. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-23.
Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Substance-Related Disorders with a site in Canada — 26 open to participants now, 29 under way, none of them phase 3. Substance-Related Disorders · Canada.
Among the 81 studies in Substance-Related Disorders with a site in Canada, this one is the 33rd largest by planned enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 19 of the 28 other live ones, and was the 72nd registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →26 of the 81 studies in Substance-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:
St. Joseph's Healthcare Hamilton · Sites in Canada
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–70
University Health Network, Toronto · Sites in Canada
Ages 18–85 · Healthy volunteers
Fraser Health · Sites in Canada
Ages 19+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Median enrollment 74 across the 71 interventional studies, 520 across the 9 observational. Of the 47 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 81 have an industry lead sponsor. The 10 most frequent:
Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Centre hospitalier de l'Université de Montréal (CHUM) has 3 studies filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
9 of the studies in Substance-Related Disorders with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04812613Ottawa Hospital Research InstituteTobacco-Concurrent Addictions in At-Risk Youth in Ottawa | 2026-12-31 |
| NCT05704582Ciusss de L'Est de l'Île de MontréalRCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders | 2027-01 |
| NCT07146633Centre for Addiction and Mental HealthEfficacy of an EMDR App for PTSD and SUD | 2027-01-30 |
| NCT03249428Ottawa Hospital Research InstituteCytisine vs Nicotine Replacement Therapy | 2027-03 |
| NCT06856161Fraser HealthA Novel Blood Test as a Biomarker in Mental Health | 2027-03-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 81 studies in Substance-Related Disorders with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Methamphetamine use disorder (MUD) is becoming an increasing public health concern in Canada. While the evidence on the efficacy and safety of prescription psychostimulants for the treatment of MUD is promising, the knowledge on the maintenance therapy using stimulant agonist therapy is scarce and needs further investigation, especially in terms of long-term retention in treatment.
The goal of this clinical trial is to evaluate the feasibility of a long-term (25 weeks) administration of high-dose stimulant agonist therapy, using Lisdexamfetamine (LDX-01) on top of treatment-as-usual (TAU), in a population of people with moderate to severe MUD, as measured by study retention, treatment retention, treatment adherence and satisfaction compared against a placebo group.
Participants will be placed randomly into one of two groups:
This trial is a single-centre, randomized double-blind (LDX-01), dose-ascending, placebo-controlled trial. This study is an extension to a parent trial, Addition of high-dose stimulant and engagement-focused contingency management, alone and in combination, to treatment as usual for the management of methamphetamine use disorder (ASCME): a pan-Canadian multi-centre, randomized, controlled trial (NCT05854667). Participants will be enrolled in one of the 2 treatment arms:
Arm 1 : TAU plus high-dose LDX-01 Arm 2 : TAU plus placebo
The trial will enroll 62-80 participants who have completed the parent trial in the Quebec site. The participants will be enrolled in the trial for 30 weeks.
Participation includes the following:
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
This study's planned enrollment of 80 is below the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Browse Substance-Related Disorders studies →Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Compared within Substance-Related Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Behavior, Addictive. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive TAU at the clinic as well as once daily over-encapsulated LDX-01 orally for 25 weeks.
Drug: LDX-01 plus TAU
Participants will receive TAU at the clinic as well as once daily LDX-01-matched placebo orally for 25 weeks.
Drug: Placebo plus TAU
Participants receive once daily LDX-01 for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases: Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25).
Participants receive once daily LDX-01-matched placebo for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases: Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25).
Retention in treatment
Retention in treatment will be measured as the proportion of study participants who receive any intervention during the 4 weeks before week 22 and 4 weeks before week 26
Time frame: Weeks 18, 19, 20, 21 and weeks 22, 23, 24, 25
Treatment satisfaction
Participant treatment satisfaction will be measured by evaluating participant satisfaction using the Client Satisfaction Questionnaire-8 (CSQ-8) questionnaire. The total score ranges from 8 (minimum) to 32 (maximum) with the higher values showing greater satisfaction.
Time frame: Weeks 22, 26
Retention in study
Retention in study will be measured as 1) the proportion of study participants who return for the study visit at week 22 with or without receiving the study interventions, 2) the proportion of study participants who return for the study visit at week 26 with or without receiving the study interventions, and 3) the proportion of study participants who return for the last study visit at week 30 with or without receiving the study interventions.
Time frame: Weeks 22, 26 and 30
Treatment adherence
Treatment adherence will be first, measured individually, as the total proportion of the number of the assigned medications (LDX-01/placebo) taken through the intervention (from baseline until the end of week 25) and then averaged across all study completers.
Time frame: from week 1 day 1 to week 25
Safety events
Safety of long-term high-dose LDX-01 will be assessed through the collection of adverse event (AEs) and serious adverse event (SAEs). The number and proportions of each AE, SAE, adverse drug reaction (ADR), and unexpected ADR will be recorded weekly. For calculations, each participant's safety-related event will be counted once under the maximum severity or the strongest recorded causal relationship to study medication
Time frame: up to 30 weeks : from the date of enrollment until week 30
QTc measurement
QTc will be measured using ECG; incidence of borderline prolonged (460-479 milliseconds for females and 450-469 milliseconds for males) and prolonged ( ≥ 480 milliseconds for females and ≥ 470 milliseconds for males) QTc interval will be measured using the Bazett method for the correction of QT interval.
Time frame: Screening, weeks 1, 2, 3, 7 and 22
Self-reported methamphetamine use
Self-reported methamphetamine use, is measured using the self-reported number of days of methamphetamine use during the 29 weeks of the study using the Timeline Follow Back (TLFB) Questionnaire since the last study visit, or in the past 28 days, whichever number of days is the least (i.e., researcher-administered, with memory cues to improve accuracy).
Time frame: Baseline, week 1 day 1, weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 26 and 30
Methamphetamine use by urinalysis
Methamphetamine use by urinalysis will be measured by the number of reactive urine samples tested for methamphetamine using the rapid chromatographic immunoassays for urine drug screen (UDS). All urine specimens will be collected and analyzed using a Rapid Response Multi- Drug One Step Screen Test Panel, following the manufacturer's recommended procedures to test for the presence of the following drugs or their respective metabolites: methamphetamine, morphine, fentanyl, benzodiazepines, cocaine, THC, methadone, buprenorphine, methylphenidate, MDMA, LSD, ketamine, oxycodone, heroin, Hydromorphone and amphetamine (week 30 only). A validity check will be performed using an adulterant strip included in the test.
Time frame: week 1 day 1, weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 26 and 30
Amphetamine craving
Amphetamine craving will be measured using the Brief Substance Craving Scale (BSCS). The BSCS is a 16-item, self-report instrument which assesses cravings for substances over 24-hour period. It has good psychometric properties. Intensity, frequency, and length of cravings are recorded on a five-point Likert scale. the total score is 0 (minimum) to 12 (maximum) with higher values indicating a larger craving.
Time frame: week 1 day 1, weeks 12, 22, 26 and 30
Addiction severity
Addiction severity is measured with the Addiction Severity Index (ASI), a Self-Report questionnaire that captures substance abuse participants' functioning. It has good psychometric properties, with good consistency and test-retest reliabilities. The ASI Self-Report assesses problem use in the past 30 days in seven areas commonly affected by substance use, including medical, employment/support, alcohol, drug, legal, family/social, and psychiatric drug sections.
Time frame: week 1 day 1, weeks 12, 22, 26 and 30
Changes in Quality of life
Quality of life will be measured using the World Health Organization Quality of Life - BREF (WHOQOL-BREF), a person-centred generic patient-reported quality of life measure, validated to document and follow changes in quality of life in different physical and psychiatric disorders. It specifically looks at 4 domains related to quality of life: physical health, psychological health, social relationships, and environment. Domain scores for the WHOQOL-BREF are calculated by taking the mean of all items included in each domain and multiplying by a factor of four. These scores are then transformed to a 0-100 scale with the higher values showing greater quality of life.
Time frame: week 1 day 1, weeks 12, 22, 26 and 30
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Aug 2027, 25 months after the start.
Of 47 non-industry phase 2 interventional studies under Substance-Related Disorders, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 51. This study's planned 25 months is below that.
Counting every sponsor, half of 51 studies reached it within 35 months; a quarter within 24 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre hospitalier de l'Université de Montréal (CHUM) →